Cover Image

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2014 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for January 2014 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2014 12
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2014 14
    • 2.2.1 McKesson Completes Acquisition of Celesio for US$8.49 Billion 14
    • 2.2.2 Edison Pharma Expands Licensing Agreement with Dainippon Sumitomo Pharma 15
    • 2.2.3 Community Health Systems Completes Private Placement of Notes for US$4 Billion 16
    • 2.2.4 Forest Lab Completes Acquisition of Aptalis Pharma from TPG Capital for US$2.9 Billion 17
    • 2.2.5 Bayer Announces Public Offering of Bonds for US$2.7 Billion 18
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2014 19
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2014 20

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2014 21
    • 3.1.1 Top M&A Deals in January 2014 22
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2013 - January 2014 23
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2014 24
    • 3.2.1 Top Equity Offering Deals in January 2014 25
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2013 - January 2014 26
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2014 27
    • 3.3.1 Top PE/VC Deals in January 2014 28
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2014 29
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2014 30
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2013-January 2014 32
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2013-January 2014 33

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2014 34

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2014 34
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2013 - January 2014 36
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2014 37
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2014 38
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 39
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2013 - January 2014 41
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2013 - January 2014 42
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 44

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2014 46

  • 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2014 46
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2014 48
    • 5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2014 49
    • 5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2014 50
    • 5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2014 50
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2013 - January 2014 51
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2013 - January 2014 53
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2013 - January 2014 55
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2013 - January 2014 57

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 59

  • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2014 59
    • 6.1.1 Oncology - Deals of the Month 60
  • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2014 62
    • 6.2.1 Central Nervous System - Deals of the Month 63
  • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2014 66
    • 6.3.1 Infectious Diseases - Deals of the Month 67
  • 6.4 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, January 2014 69
    • 6.4.1 Metabolic Disorders - Deal of the Month 70
  • 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2014 72
    • 6.5.1 Immunology - Deal of the Month 73
  • 6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2014 74
    • 6.6.1 Cardiovascular - Deal of the Month 75
  • 6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, January 2014 77
    • 6.7.1 Gastrointestinal - Deals of the Month 78

7 Deal Summary by Geography 79

  • 7.1 Pharmaceuticals & Healthcare, North America Deals, January 2014 79
    • 7.1.1 North America - Deals of the Month 80
  • 7.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2014 82
    • 7.2.1 Europe - Deals of the Month 83
  • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2014 85
    • 7.3.1 Asia-Pacific - Deals of the Month 86
  • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2014 88
    • 7.4.1 Rest of the World - Deals of the Month 89

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 90

  • 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2013 - January 2014 90
  • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2013 - January 2014 92

9 Further Information 93

  • 9.1 Methodology 93
  • 9.2 About GlobalData 94
  • 9.3 Disclosure information 95
  • 9.4 Disclaimer 95

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 13
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2014 14
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2014 20
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 22
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2014 22
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2013 - January 2014 23
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 25
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2014 25
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 26
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 28
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2014 28
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2013 - January 2014 29
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2014 31
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 32
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2013 - January 2014 33
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 35
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 36
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 37
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2014 38
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 40
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2013 - January 2014 43
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2013 - January 2014 45
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 47
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 49
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2014 49
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2014 50
  • Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2014 50
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 52
  • Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2014 54
  • Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2013 - January 2014 56
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2014 58
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 60
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 63
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 67
  • Table 35: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 70
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 73
  • Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 75
  • Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 78
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 80
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 83
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 86
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 89
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 91
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 92

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 12
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), January 2014 19
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2014 20
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 21
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2013 - January 2014 23
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 24
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 26
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 27
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2013 - January 2014 29
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2014 30
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2014 31
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 32
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 34
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 36
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 37
  • Figure 16:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 39
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2013 - January 2014 41
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2013 - January 2014 42
  • Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 44
  • Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 46
  • Figure 21:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 48
  • Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 51
  • Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2013 - January 2014 53
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2013 - January 2014 55
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2013 - January 2014 56
  • Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2014 57
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 59
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 62
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 66
  • Figure 30: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 69
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 72
  • Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 74
  • Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 77
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 79
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 82
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 85
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 88
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 90
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2013 - January 2014 92
Show More
Pricing
Get Notified
Email me when related reports are published